Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rocket Pharmaceuticals, Inc. - Common Stock
(NQ:
RCKT
)
3.840
-0.010 (-0.26%)
Streaming Delayed Price
Updated: 11:23 AM EDT, Oct 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rocket Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 23, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
October 14, 2025
FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by March 2026.
Via
Benzinga
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
October 14, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 14, 2025
Via
Benzinga
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
October 14, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
October 03, 2025
The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya.
Via
Stocktwits
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
September 04, 2025
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.
Via
Benzinga
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
August 21, 2025
Via
Benzinga
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
August 21, 2025
Via
Benzinga
Which stocks are experiencing notable movement on Wednesday?
August 20, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
August 20, 2025
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.
Via
Stocktwits
Topics
Death
Traders are paying attention to the gapping stocks in Wednesday's session.
August 20, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Via
Chartmill
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday
August 20, 2025
Via
Benzinga
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
August 20, 2025
Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and updated treatment protocol.
Via
Benzinga
Wednesday's pre-market session: top gainers and losers
August 20, 2025
As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
August 20, 2025
Via
Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
August 20, 2025
Via
Benzinga
Why Is Rocket Pharma Stock Up 15% Pre-Market Today?
August 20, 2025
The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.
Via
Stocktwits
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
August 11, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
August 11, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
August 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
August 08, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)
August 08, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)
August 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Rocket (RCKT) Q2 Loss Narrows 16%
August 07, 2025
Via
The Motley Fool
Topics
Intellectual Property
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
August 07, 2025
From
Rocket Pharmaceuticals, Inc.
Via
Business Wire
RCKT DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT
August 07, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.